209 results on '"Kotapati, S."'
Search Results
2. Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
3. Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
4. 816P Investigating surrogate endpoints (SE) for overall survival (OS) in first-line (1L) advanced melanoma: A pooled-analysis of immune checkpoint inhibitor (ICI) trials
5. Effect of the Ni81Fe19 thickness on the magnetic properties of Ni81Fe19/Fe50Co50 bilayers
6. Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
7. POSC308 Network Meta-Analysis Under Survival Heterogeneity with Long-Term Survival: A Case Study from Adjuvant Treatment of Resected Stage III/IV Melanoma
8. 1077P Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE)
9. Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy : A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE)
10. PCN193 Assessing the Impact of Modeling Non-Disease-Related Mortality on Long-Term Survivorship Rates in Previously Untreated Advanced Melanoma: A Case Study from CheckMate 067
11. 111P Application of radiomics signatures and unidimensional vs volumetric measurement of early tumor growth dynamics (TGD) to predict first-line treatment outcomes in patients with stage IV non-small cell lung cancer (NSCLC)
12. Résultats en vie réelle chez les patients recevant du nivolumab 480 mg toutes les 4 semaines par rapport à d’autres schémas posologiques dans le traitement du mélanome en adjuvant
13. IMAGE: A ‘real world’ multinational observational study in patients with advanced melanoma
14. 1105P Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III CheckMate 067 trial
15. PCN440 NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS: HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE)
16. PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
17. Mixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial
18. Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: A network meta-analysis
19. Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
20. PCN91 HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
21. PRM23 - MODELLING CANCER TREATMENTS IN THE ADJUVANT SETTING: A TARGETED LITERATURE REVIEW (TLR) OF TECHNOLOGY APPRAISALS (TA) OF ADJUVANT THERAPIES SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) AND A CASE STUDY IN ADJUVANT MELANOMA.
22. PRM21 - MODELLING SURVIVAL OF PATIENTS WITH COMPLETELY RESECTED ADVANCED MELANOMA WITH ADJUVANT TREATMENT OF NIVOLUMAB VERSUS OBSERVATION
23. Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
24. Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
25. Cost-Effectiveness of Nivolumab (NIVO) Combined with Ipilimumab (IPI) Compared with Nivo and Ipi Monotherapies in The First-Line Treatment of Advanced Melanoma in The United States: Analysis Using 28-Month Overall Survival (OS) Data from Checkmate 067
26. 1348P - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
27. 1347P - Long-term efficacy of combination nivolumab and ipilimumab for first-line treatment of advanced melanoma: A network meta-analysis
28. 1331P - Mixture-cure modeling for resected stage III/IV melanoma in the phase III CheckMate 238 trial
29. Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067
30. Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced Melanoma
31. Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden
32. Combined XRD and EXAFS study of Cr-Al-N gradient samples
33. Health Care Cost Comparison Analysis of Nivolumab + Ipilimumab Regimen and Nivolumab Monotherapy Versus Established Advanced Melanoma Therapies Utilizing Clinical Trial and Real-World Data
34. Predictors of Utility Over Time among Patients with Treatment-Naïve Advanced Melanoma from the Phase 3 Checkmate 067 Trial
35. Health Care Resource Utilization among Advanced Melanoma Patients in Europe
36. Health Care Cost Comparison Analysis of Nivolumab + Ipilimumab Regimen, Nivolumab Monotherapy, and Ipilimumab Monotherapy Utilizing Clinical Trial Data: A European Perspective
37. Treatment Patterns among Advanced Melanoma Patients in Europe
38. Preference-Based Utilities for Adjuvant Melanoma in the United Kingdom and Australia
39. In situ control of the structure formation of magnetron sputtered Vanadium carbide coatings: periodic modulation of the microstructure
40. In situ X-Ray Reflectivity measurements during sputtering of vanadium carbide thin films
41. In-stiu X-ray reflectivity measurements during DC sputtering of vanadium carbide thin films
42. PCN135 - Cost-Effectiveness of Nivolumab (NIVO) Combined with Ipilimumab (IPI) Compared with Nivo and Ipi Monotherapies in The First-Line Treatment of Advanced Melanoma in The United States: Analysis Using 28-Month Overall Survival (OS) Data from Checkmate 067
43. Angle-resolved X-ray reflectivity measurements during off-normal sputter deposition of VN
44. 3338 Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE)
45. Conditional Survival Probabilities for Previously Untreated Advanced Melanoma Patients Receiving Ipilimumab: Model Based Analysis
46. Cost-Effectiveness of Ipilimumab in Previously Untreated Patients for Advanced Melanoma in Sweden
47. Major groove orientation of the (2S)-N6-(2-hydroxy-3-buten-1-yl)-2'-deoxyadenosine DNA adduct induced by 1,2-epoxy-3-butene
48. 1115P - Cost-effectiveness of nivolumab+ipilimumab in first-line treatment of advanced melanoma: Analysis using 28-month overall survival from CheckMate 067
49. Relapse-Free Survival (Rfs) As a Surrogate Endpoint for Overall Survival (Os) in Adjuvant Interferon Trials in Patients (Pts) with Resectable Cutaneous Melanoma: an Individual Patient Data (Ipd) Meta-Analysis
50. The Relative Clinical and Economic Value of Ipilimumab as First-Line Treatment of Metastatic Melanoma Versus Other Anti-Cancer Agents for Metastatic Diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.